IMB-401

IMB-401 is an investigational oncology therapeutic being developed by IMBiologics using its proprietary STAM (Specific Target-Activatable Modality) platform. The STAM technology is designed to create conditionally active biologics, often referred to as 'masked' antibodies or pro-antibodies. These molecules are engineered to remain functionally silent in systemic circulation and healthy tissues to minimize off-target toxicities. Upon entering the tumor microenvironment, the therapeutic is activated—typically through the cleavage of a masking peptide by tumor-specific proteases—allowing it to bind to its intended target and exert anti-tumor activity. As of current pipeline disclosures, the specific molecular target of IMB-401 remains undisclosed, and the candidate is in early-stage development for the treatment of various cancers.

Other names

STAM